Imperial College London
Portrait Picture

DrRuiPinto

Faculty of Medicine, School of Public Health

Research Associate in Chemometrics/Metabolomics
 
 
 
//

Contact

 

+44 (0)20 7594 9761r.pinto Website

 
 
//

Location

 

155Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lomnytska:2018:10.1186/s40364-018-0118-y,
author = {Lomnytska, M and Pinto, R and Becker, S and Engström, U and Gustafsson, S and Björklund, C and Templin, M and Bergstrand, J and Xu, L and Widengren, J and Epstein, E and Franzén, B and Auer, G},
doi = {10.1186/s40364-018-0118-y},
journal = {Biomarker Research},
title = {Platelet protein biomarker panel for ovarian cancer diagnosis},
url = {http://dx.doi.org/10.1186/s40364-018-0118-y},
volume = {6},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Platelets support cancer growth and spread making platelet proteins candidates in the search for biomarkers. Methods: Two-dimensional (2D) gel electrophoresis, Partial Least Squares Discriminant Analysis (PLS-DA), Western blot, DigiWest. Results: PLS-DA of platelet protein expression in 2D gels suggested differences between the International Federation of Gynaecology and Obstetrics (FIGO) stages III-IV of ovarian cancer, compared to benign adnexal lesions with a sensitivity of 96% and a specificity of 88%. A PLS-DA-based model correctly predicted 7 out of 8 cases of FIGO stages I-II of ovarian cancer after verification by western blot. Receiver-operator curve (ROC) analysis indicated a sensitivity of 83% and specificity of 76% at cut-off >0.5 (area under the curve (AUC) = 0.831, p < 0.0001) for detecting these cases. Validation on an independent set of samples by DigiWest with PLS-DA differentiated benign adnexal lesions and ovarian cancer, FIGO stages III-IV, with a sensitivity of 70% and a specificity of 83%. Conclusion: We identified a group of platelet protein biomarker candidates that can quantify the differential expression between ovarian cancer cases as compared to benign adnexal lesions.
AU  - Lomnytska,M
AU  - Pinto,R
AU  - Becker,S
AU  - Engström,U
AU  - Gustafsson,S
AU  - Björklund,C
AU  - Templin,M
AU  - Bergstrand,J
AU  - Xu,L
AU  - Widengren,J
AU  - Epstein,E
AU  - Franzén,B
AU  - Auer,G
DO  - 10.1186/s40364-018-0118-y
PY  - 2018///
SN  - 2050-7771
TI  - Platelet protein biomarker panel for ovarian cancer diagnosis
T2  - Biomarker Research
UR  - http://dx.doi.org/10.1186/s40364-018-0118-y
UR  - http://hdl.handle.net/10044/1/68762
VL  - 6
ER  -
Download